摘要
目的观察甲状腺乳头状癌(PTC)组织中肿瘤坏死因子受体相关蛋白1(TRAP1)表达、V-raf鼠类肉瘤滤过性病毒致癌基因同源体B1(BRAF)V_(600E)基因突变情况,并分析其相关性。方法 PTC组织100例份(A组)、甲状腺腺瘤组织38例份(B组)、结节性甲状腺肿组织38例份(C组),观察各组TRAP1蛋白表达及BRAFV_(600E)基因突变情况,分析TRAP1表达、BRAFV_(600E)基因突变两者间的相关性及其与PTC临床病理特征的关系。结果A、B、C组TRAP1阳性率分别为71.00%、13.16%、10.53%,BRAFV_(600E)基因突变率分别为52.00%、0、0,A组分别与B、C组比较,P均<0.05。BRAFV_(600E)基因突变与PTC患者年龄及肿瘤直径相关(P均<0.05)。A组中TRAP1表达与BRAFV_(600E)基因突变呈正相关(r=0.445,P<0.05)。结论 PTC组织中TRAP1阳性率及BRAFV_(600E)基因突变率升高,且TRAP1高表达与BRAFV_(600E)基因突变密切相关,两者可能共同参与了PTC的发生发展。
Objective To study the expression of tumor necrosis factor receptor-associated factor 1(TRAP1)and V-raf murine sarcoma viral oncogene homolog B1 V600E gene(BRAF V600E gene)mutation in the papillary thyroid cancer(PTC)and to analyze the correlation between TRAP1 and BRAF V600E gene mutation.Methods One hundred cases of PTC tissues(group A),38 cases of thyroid adenoma tissues(group B),and 38 cases of nodular goiter tissues(group C)were selected.TRAP1 protein expression and BRAF V600E gene mutation in each group were observed,and then we analyzed the correlation between TRAP1 expression and BRAF V600E gene mutation as well as its relationship with clinicopathological characteristics of PTC.Results In the groups A,B,and C,the positive rates of TRAP1 were 71%,13.16%,and 10.53%,respectively,and the mutation rates of BRAF V600E gene were 52%,0,and 0,respectively;significant difference was found between group A and group B,and between group A and group C,all P<0.05.BRAF V600E gene mutation was associated with the age and tumor diameter(both P<0.05).The TRAP1 expression was positively correlated with BRAF V600E gene mutation in the group A(r=0.445,P=0.000).Conclusion The positive rate of TRAP1 and the mutation rate of BRAF V600E gene increase in the PTC tissues,the BRAF V600E gene mutation is closely related to the high expression of TRAP1,and both of them may participate in the occurrence and development of PTC.
作者
梁慧玲
贺晓燕
杨文秀
王龙
杨勇
LIANG Huiling;HE Xiaoyan;YANG Wenxiu;WANG Long;YANG Yong(Guizhou Medical University,Guiyang 550004,China)
出处
《山东医药》
CAS
2018年第11期22-25,共4页
Shandong Medical Journal
基金
贵州省科学技术基金资助项目(黔科合J字[2012]2036号)